Treatment with recombinant FGF19 was found to signicantly reduce the pathological hallmarks of NASH in the multi-tissue liver organoid-based steatosis model, such as lipid accumulation, hepatocyte damage, stiffness, and ROS production. This evidence concerns the gene FGF19 and steatosis.